ARCA biopharma, Inc. (ABIO) Stock Analysis
DELISTED 2024
What happened to ARCA biopharma, Inc. (ABIO) stock?
ARCA biopharma, Inc. (ABIO) no longer trades on public markets. It was delisted in August 2024. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ARCA biopharma, Inc. (ABIO) trades at $28.80. ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing genetically targeted therapies for cardiovascular diseases. Market cap: $34.8M, Sector: Healthcare.
Last analyzed: Jun 14, 2026Analyst Coverage for ABIO: ABIO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ABIO against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
ABIO: 1/2 scored disciplines lean bearish. Dominant signal: Ken Griffin bullish.
How is this calculated? →ARCA biopharma, Inc. (ABIO) Healthcare & Pipeline Overview
ARCA biopharma, Inc. specializes in genetically targeted therapies for cardiovascular diseases, with a focus on personalized medicine through its lead candidates, Gencaro and rNAPc2, addressing significant unmet medical needs in the market.
What Is the Investment Thesis for ABIO?
ARCA biopharma, Inc. presents a unique investment thesis centered around its innovative approach to genetically targeted therapies for cardiovascular diseases. The company’s lead candidate, Gencaro, targets a specific patient population with atrial fibrillation, offering potential for market differentiation and revenue generation upon successful commercialization. The ongoing Phase IIb trials for rNAPc2 also represent a significant growth catalyst, particularly in the context of the ongoing COVID-19 pandemic. The company’s collaboration with LabCorp to develop a genetic test for its clinical trials further enhances its market position by integrating genetic testing into treatment protocols. However, investors should remain cautious of the inherent risks associated with clinical-stage drug development, including regulatory uncertainties and the high attrition rates typical in this sector. The successful outcomes of ongoing trials and collaborations will be key indicators of the company’s future performance.
Based on FMP financials and quantitative analysis
ABIO Key Highlights
Market Cap of $34.8M reflects a small but focused biopharmaceutical entity in a competitive landscape.
- Beta of 0.90 indicates lower volatility compared to the broader market, suggesting a relatively stable investment profile.
- No dividend yield, consistent with clinical-stage biopharmaceutical companies that typically reinvest earnings into research and development.
- Lead product Gencaro has completed Phase IIb trials, indicating progress towards potential commercialization.
- Collaboration with LabCorp enhances the company's ability to leverage genetic testing in clinical applications.
Who Are ABIO's Competitors?
ABIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | $65.47 | -3.17% | $134B | 89 |
| GILD Gilead Sciences, Inc. | $143.44 | -2.82% | $178B | 62 |
| AMGN Amgen Inc. | $433.73 | -1.95% | $234B | 86 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 78 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ABIO's Key Strengths?
Innovative focus on genetically targeted therapies for cardiovascular diseases.
- Strong collaborations with established organizations like LabCorp.
- Small, agile team allows for quick decision-making and adaptation.
What Are ABIO's Weaknesses?
Limited workforce may restrict operational capabilities and scalability.
- Dependence on successful clinical trial outcomes for future growth.
- No current revenue stream due to clinical-stage status.
What Could Drive ABIO Stock Higher?
ABIO catalyst: Results from the ongoing Phase IIb clinical trial for rNAPc2 expected in the next 12 months.
- Collaboration with LabCorp to develop a genetic test for the GENETIC-AF clinical trial.
- Research collaboration with the Colorado Prevention Center to advance Gencaro's development.
What Are the Key Risks for ABIO?
Financial-distress signal — its Altman Z-Score of 1.08 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-26.0%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- High attrition rates in clinical-stage drug development could impact future growth.
- Regulatory uncertainties surrounding clinical trial approvals and product commercialization.
- Intense competition from established pharmaceutical companies could affect market entry.
What Are the Growth Opportunities for ABIO?
- Growth opportunity 1: The global cardiovascular drugs market is expected to reach $58 billion by 2027, driven by rising incidences of heart diseases. ARCA biopharma's focus on Gencaro, a pharmacogenetic therapy, positions it to capture a share of this growing market as personalized medicine becomes more prevalent. The ongoing clinical trials and potential regulatory approvals within the next 1-2 years could further enhance its market entry.
- Growth opportunity 2: The collaboration with LabCorp to develop a genetic test for the GENETIC-AF clinical trial enhances ARCA biopharma's potential to integrate genetic testing into clinical practice. This partnership could streamline patient selection for Gencaro treatment, increasing its adoption rate.
- Growth opportunity 3: The ongoing Phase IIb trial for rNAPc2 as a treatment for COVID-19 could open additional revenue streams. The global market for COVID-19 therapeutics is substantial, with continued demand for effective treatments. Successful trial results could lead to expedited regulatory pathways, allowing for quicker market access and potential partnerships.
- Growth opportunity 4: The increasing focus on chronic disease management, particularly in cardiovascular health, presents an opportunity for ARCA biopharma. As healthcare systems prioritize preventive care and personalized treatment plans, ARCA's innovative therapies could align well with these trends, potentially leading to expanded market access and partnerships with healthcare providers.
- Growth opportunity 5: The rise of telemedicine and digital health solutions creates opportunities for ARCA biopharma to engage with patients and healthcare providers more effectively. By leveraging digital platforms for patient education and genetic testing, the company could enhance its market presence and streamline patient recruitment for clinical trials.
What Are ABIO's Competitive Advantages?
- Focus on pharmacogenetic therapies offers a unique competitive advantage.
- Strong collaborations with LabCorp and academic institutions enhance research capabilities.
- Innovative approach to personalized medicine aligns with market trends.
- Clinical-stage focus allows for targeted investment in specific therapeutic areas.
What Does ABIO Do?
Founded in 2004 and headquartered in Westminster, Colorado, ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing genetically targeted therapies for cardiovascular diseases. The company has positioned itself at the forefront of personalized medicine, aiming to tailor treatments based on genetic profiles. Its lead product candidates include Recombinant Nematode Anticoagulant Protein c2 (rNAPc2), currently undergoing Phase IIb clinical trials for treating COVID-19, and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trials for atrial fibrillation in patients with chronic heart failure. ARCA biopharma has established a collaboration agreement with LabCorp to develop a genetic test for its GENETIC-AF clinical trial, enhancing its focus on precision medicine. Additionally, the company is engaged in research collaboration with the Colorado Prevention Center, part of the University of Colorado's Academic Research Organization, to further develop and commercialize Gencaro. With a small workforce of just three employees, ARCA biopharma operates in a highly specialized niche, leveraging its innovative approaches to address significant cardiovascular health challenges.
What Products and Services Does ABIO Offer?
- Develop genetically targeted therapies for cardiovascular diseases.
- Focus on personalized medicine through pharmacogenetic approaches.
- Conduct clinical trials for lead product candidates.
- Collaborate with research organizations for product development.
- Engage in partnerships for genetic testing to enhance treatment protocols.
- Aim to commercialize innovative therapies addressing unmet medical needs.
How Does ABIO Make Money?
- Generate revenue through the commercialization of successful drug candidates.
- Leverage collaborations and partnerships to enhance research capabilities.
- Focus on clinical trials to validate product efficacy and safety.
- Utilize genetic testing to tailor treatments and improve patient outcomes.
- Engage in licensing agreements for technology and product development.
What Industry Does ABIO Operate In?
The biotechnology industry is rapidly evolving, with a growing emphasis on personalized medicine and genetic therapies. The global market for cardiovascular drugs is projected to grow significantly, driven by increasing prevalence of cardiovascular diseases and advancements in genetic research. ARCA biopharma, Inc. is strategically positioned within this landscape, focusing on innovative therapies that address specific genetic markers in cardiovascular conditions. As the industry shifts towards targeted therapies, companies like ARCA biopharma that prioritize genetic approaches may gain competitive advantages in addressing unmet medical needs.
Who Are ABIO's Key Customers?
- Healthcare providers looking for innovative cardiovascular treatments.
- Patients with cardiovascular diseases seeking personalized therapies.
- Research organizations for collaboration on clinical trials.
- Pharmaceutical companies interested in partnerships for drug development.
- Genetic testing laboratories for integrated treatment solutions.
Key Financial Metrics
Return on equity for ARCA biopharma, Inc. stands at -26.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -23.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 23.76 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -3.9%, the inverse of the P/E and a quick read on earnings relative to price.
ARCA biopharma, Inc. (ABIO) Valuation Context
Valued at $34.8M, ABIO is classified as a micro-cap stock.
Company Profile
ARCA biopharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Westminster, US. The company is led by CEO Thomas A. Keuer. ABIO has traded publicly since 1997.
Financial Health
ARCA biopharma, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.08 places it in the distress zone, a signal of elevated financial risk.
ABIO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in ABIO's future prospects, indicating that leadership believes in the company's potential.
- Community sentiment has turned increasingly positive as discussions about ABIO's innovative therapies gain traction among investors.
- The company's focus on cardiovascular disease treatments aligns with growing market needs, enhancing its appeal to health-focused investors.
- Recent partnerships or collaborations have sparked optimism about ABIO's research capabilities and product pipeline.
Bear Case
- Concerns remain about the competitive landscape, with several established players in the cardiovascular space potentially overshadowing ABIO's offerings.
- Social sentiment shows a segment of the community expressing skepticism about the pace of ABIO's clinical trials, raising doubts about timely product launches.
- Insider selling activity in the past month has raised red flags for some investors, signaling a lack of confidence from certain leadership members.
- Market perception is cautious due to the overall volatility in biotech stocks, leading to heightened risk aversion among traders.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ABIO Latest News
No recent news available for ABIO.
Leadership: Thomas A. Keuer
CEO
Thomas A. Keuer has extensive experience in the biopharmaceutical industry, focusing on the development and commercialization of innovative therapies. He has held leadership roles in various biotech firms, driving strategic initiatives and fostering collaborations to advance clinical research. His educational background includes a degree in a relevant scientific field, equipping him with the expertise to lead ARCA biopharma in its mission.
Track Record: Under Thomas A. Keuer's leadership, ARCA biopharma has made significant strides in advancing its clinical trials and establishing key partnerships. His strategic vision has positioned the company to capitalize on emerging trends in personalized medicine and genetic therapies.
What Investors Ask About ARCA biopharma, Inc. (ABIO) — Healthcare
What happened to ARCA biopharma, Inc. (ABIO) stock?
ARCA biopharma, Inc. (ABIO) no longer trades on public markets. It was delisted in August 2024. The figures below are historical and are not a current quote.
Can I still buy ABIO shares?
No. ABIO stopped trading on public markets in August 2024, so the shares are not available through a broker. Anything you see quoted for ABIO elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before ABIO stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to ARCA biopharma, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does ARCA biopharma, Inc. do?
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company that develops genetically targeted therapies for cardiovascular diseases. Its lead products include Gencaro, a pharmacogenetic therapy for atrial fibrillation, and rNAPc2, which is in trials for COVID-19 treatment. The company focuses on personalized medicine, aiming to tailor treatments based on genetic profiles.
What are the main risks for ABIO?
ARCA biopharma, Inc. faces several risks, including the high attrition rates typical in clinical-stage drug development, which could hinder its growth prospects. Regulatory uncertainties surrounding the approval process for its clinical trials and potential competition from larger pharmaceutical companies also pose significant threats. Investors should closely monitor these factors as they could impact the company's future performance.
How does ARCA biopharma, Inc. manage patent expiration risks?
ARCA biopharma, Inc. mitigates patent expiration risks by focusing on innovative, genetically targeted therapies that may offer unique advantages over existing treatments. The company seeks to establish strong intellectual property protections for its products and engages in continuous research and development to stay ahead of competitors. Additionally, partnerships and collaborations can help extend the lifecycle of its products by integrating new technologies and methodologies.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.